ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 579

Patients with Ankylosing Spondylitis Do Not Adapt to Their Disease: Evidence from the ‘then Test’ in Patients Treated with TNF-Inhibitors

Ivette Essers1, Astrid Van Tubergen1,2, Jurgen Braun3, Xenofon Baraliakos3, Frank Heldmann3 and Annelies Boonen4,5, 1School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, 2Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands, 5Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ankylosing spondylitis (AS) and well-being, Biologics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Although never formally studied, rheumatologists feel that patients with ankylosing spondylitis (AS) tend to adjust to their disease. Response shift is one of the theories to demonstrate that adaptation takes place and makes use of the ‘then test’. A ‘then test’ asks patients to re-rate their past health in a situation where change in health occurred. This theory states that patients with a treatment response would re-rate their former health as worse as initially thought, and that the magnitude of treatment response is associated with a larger gap between the initial and retrospective assessment of health. The aim of the present study was to understand whether patients with AS adapt to their disease, using the ‘then test’, in patients in whom infliximab (INF) was started. It was hypothesized responders to therapy would re-rate retrospectively their initial health as worse.

Methods: Data were used from 103 European patients who participated in the AS Study for the Evaluation of Recombinant INF Therapy (ASSERT) and continued in the European AS INF Cohort (EASIC). The Bath AS Global Score (BAS-G) last week was used to assess patient global well-being. A BAS-G ‘then test’ was integrated in EASIC, and asked patients to re-rate their initial well-being (i.e. before the start of INF in ASSERT). Treatment response between ASSERT and EASIC was assessed with the Assessment of SpondyloArthritis International Society 20 (ASAS20) response criteria. The baseline BAS-G of ASSERT and retrospective BAS-G of ASSERT were compared using paired t-test. Limits of agreement were calculated. A linear regression analysis was performed to identify whether response influenced the difference between the initial and retrospective BAS-G of ASSERT (i.e. gap) after adjusting for other covariates.  

Results: 86 Patients contributed to the current analyses (mean age 39.6 years (SD 10.6); mean disease duration 9.7 years (SD 8.1), and 68/96 (79.1%) patients had an ASAS20 response). At baseline, the BAS-G in ASSERT was 7.0 (SD 1.6), and patients retrospectively re-rated their BAS-G, using the ‘then test’, at 7.2 (SD 2.3), revealing a non-significant and non-relevant gap of 0.2 (SD 2.7) (p=0.45). Limits of agreements show that the gap varied between -5.1 and 5.5. In a multivariable model, the difference between the baseline BAS-G of ASSERT and retrospective BAS-G of ASSERT was irrespective of treatment response, and was only associated with the baseline BAS-G of ASSERT (p<0.01) and the BASDAI (p=0.02) before the start of INF.  

Conclusion: Patients with AS were able to retrospectively judge their well-being, even if substantial time relapsed between the start of the treatment and this retrospective assessment, and irrespective of treatment response. In this setting, the ‘then test’ could not prove adaptation by response shift in AS.


Disclosure:

I. Essers,
None;

A. Van Tubergen,
None;

J. Braun,
None;

X. Baraliakos,
None;

F. Heldmann,
None;

A. Boonen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-ankylosing-spondylitis-do-not-adapt-to-their-disease-evidence-from-the-then-test-in-patients-treated-with-tnf-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology